The nominations for this year's The Pathologist Power List are open.
11/04/2022 | George Francis Lee
By uniting three medical disciplines, can we predict the effectiveness of non-small cell lung cancer treatment?
11/03/2022 | Georgia Hulme | 2 min read
Investigating ethnic disparities in esophageal adenocarcinoma and prostate cancer
10/31/2022 | George Francis Lee | 2 min read
How advances in our understanding of intratumor heterogeneity (ITH) may lay a path for new clinical applications
10/27/2022 | George Francis Lee
Can a “plasma-first” approach to biopsy result in better testing for lung cancer?
10/25/2022 | Ofer Sharon | 5 min read
Overcoming lung cancer treatment resistance requires predictive biomarkers that take into account patient variability
10/12/2022 | George Francis Lee | 3 min read
The latest research news and views from the molecular pathology landscape
10/03/2022 | Dean Bitan | 4 min read
In an aging world with cancer cases increasing, it’s time for technology
09/30/2022 | Jeremiah McDole | 4 min read
Minimal residual disease testing could help more patients beat cancer – but first, we need tests that are precise, sensitive, and accurate enough
09/29/2022 | Yvonne Wallis, James Beasley | 6 min read
Size isn’t everything when it comes to next-generation sequencing. For one NHS consortium, using multiple panels is changing the game
09/19/2022 | Ori Zelichov | 4 min read
Not all patients respond to cancer immunotherapy – so how can we identify those who won’t and seek out better treatment options for them?
Register to access our FREE online portfolio, request the magazine in print and manage your preferences.
Register
To Screen, or not to Screen?
Women in Pathology
The Matchmakers